DelveInsight’s “Invasive Candidiasis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Invasive Candidiasis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Invasive Candidiasis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Invasive Candidiasis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Invasive Candidiasis: An Overview
According to the Centers for Disease Control and Prevention (CDC), invasive candidiasis (IC) is an infection caused by a yeast called Candida. Unlike Candida infections in the mouth and throat, which are localized to one part of the body, IC is a serious infection that can affect the blood, heart, brain, eyes, bones, or other parts of the body. A Candida bloodstream infection, also called candidemia, is the most common form of invasive candidiasis.
People who are at high risk for developing invasive candidiasis include those who: are admitted to the ICU, have a weakened immune system, have recently had surgery, have recently received lots of antibiotics in the hospital, have kidney failure, or are on hemodialysis, have diabetes and are pre-term babies.
The prophylactic and empirical or pre-emptive strategies for the management of Invasive Candidiasis include Echinocandins antifungals as the class of choice among other antifungals due to fungicidal action. Azole antifungals are second-line agents that are given for prophylaxis in both adult and pediatric patients. Amphotericin B is well-tolerated and safe for pediatric patients.
The accessibility of novel compounds may help to address some of the issues noted and broaden the range of already available choices for treating ambulant patients and managing persistent Candida infections.
Invasive Candidiasis Market Key Facts
According to a study by CDC , candidemia is one of the most common bloodstream infections in the United States. During 2013–2017, the average incidence (rate of new infections) was approximately 9 per 100,000 people; however, this number varies substantially by geographic location and patient population. CDC estimated that approximately 25,000 cases of candidemia occur nationwide each year.
As per Frederic et al. , Denmark had a rate similar to that seen in the US at 10/100 000, but by 2009 that decreased to 8.6/100 000.
According to Puig-Asensio , population-based surveillance from the US suggested that the mortality was 29% However the mortality was similar in Spain also, about 31%.
According to a study by Frederic et al. , the incidence of Invasive Candidiasis in US cities dropped from 14.1 and 30.9 cases per 100 000 persons to 9.5 and 14.4/100 000, a decline of 33% and 54%, respectively, over the 5-year period between 2008 and 2013.
As per the study by Frederic et al. , the incidence of Invasive Candidiasis in the neonatal population is higher, which was 33.8/100 000, followed by the geriatric population compared to adults in the US and the EU-5.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Invasive Candidiasis pipeline therapies. It also thoroughly assesses the Invasive Candidiasis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Invasive Candidiasis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Invasive Candidiasis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Invasive Candidiasis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Invasive Candidiasis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Invasive Candidiasis Epidemiology, Segmented as –
Total Incident Cases of Invasive Candidiasis in the 7MM (2019–2032)
Incident Cases of Invasive Candidiasis by Types in the 7MM (2019–2032)
Incident Cases of Invasive Candidiasis by Age in the 7MM (2019–2032)
Invasive Candidiasis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Invasive Candidiasis market or expected to be launched during the study period. The analysis covers the Invasive Candidiasis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Invasive Candidiasis drugs based on their sale and market share.
The report also covers the Invasive Candidiasis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Invasive Candidiasis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Invasive Candidiasis Market Will Evolve and Grow by 2032 @
Invasive Candidiasis Therapeutics Analysis
Invasive Candidiasis is the most common critical care-associated fungal infection, with a crude mortality of ~ 40–55%. The key challenges associated with IC treatment include the shift in Candida epidemiology across the globe to more resistant non-albicans species, in particular, the emergence of multiresistant Candida glabrata and Candida auris, which pose significant treatment and infection control challenges in patient care. The other barrier is the selection of the most appropriate antifungal to use in critical care patients.
Recently, GSK and SCYNEXIS have entered an exclusive agreement to commercialize and further develop Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infections. This exclusive license agreement gives GSK rights to continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis
In January 2020, the US FDA approved MYCAMINE (Astellas Pharma) for the treatment of Invasive Candidiasis in pediatric patients younger than 4 months of age.
In August 2022, Mundipharma announced that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for rezafungin for the treatment of Invasive Candidiasis in adults.
Invasive Candidiasis Companies Actively Working in the Therapeutics Market Include
Cidara Therapeutics Inc.
And Many Others
Emerging and Marketed Invasive Candidiasis Therapies Covered in the Report Include:
BREXAFEMME (ibrexafungerp): Scynexis/GSK
Fosmanogepix (APX001): Pfizer
REZZAYO (Rezafungin): Cidara Therapeutics Inc./ Mundipharma
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Invasive Candidiasis Competitive Intelligence Analysis
4. Invasive Candidiasis Market Overview at a Glance
5. Invasive Candidiasis Disease Background and Overview
6. Invasive Candidiasis Patient Journey
7. Invasive Candidiasis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Invasive Candidiasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Invasive Candidiasis Unmet Needs
10. Key Endpoints of Invasive Candidiasis Treatment
11. Invasive Candidiasis Marketed Therapies
12. Invasive Candidiasis Emerging Drugs and Latest Therapeutic Advances
13. Invasive Candidiasis Seven Major Market Analysis
14. Attribute Analysis
15. Invasive Candidiasis Market Outlook (In US, EU5, and Japan)
16. Invasive Candidiasis Companies Active in the Market
17. Invasive Candidiasis Access and Reimbursement Overview
18. KOL Views on the Invasive Candidiasis Market
19. Invasive Candidiasis Market Drivers
20. Invasive Candidiasis Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Skin Burns Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Skin Burns market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Skin Burns market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States